Zealand Pharma A/S of Denmark has become the latest European biotech company to consider listing on the Nasdaq over-the-counter market in the US in order to raise capital to expand its business. The company has one product on the market for diabetes.
Three multiple myeloma studies in which Merck & Co’s checkpoint inhibitor Keytruda (pembrolizumab) was being investigated in combination with drugs produced by Celgene Corp have been stopped following patient deaths, Merck announced on 5 July.
A UK life science incubator located in the city of Nottingham has expanded its premises in order to accommodate more than 700 new bioscience positions over the next 30 years. The expansion will be a significant boost to the economy of the Midlands region of England.
Immunocore Ltd has made further progress with its T cell receptor technology following a decision by its partner GlaxoSmithKline Plc (GSK) to select a third target for an oncology programme directed against multiple cancers.
A UK-based company that uses artificial intelligence for drug discovery has entered into a collaboration with GlaxoSmithKline Plc to discover candidate small molecules against up to 10 disease-related targets. Exscientia Ltd is a 2012 spin-out of the University of Dundee.
TiGenix has joined the growing number of European companies with a presence in the US to open an office in Cambridge, Massachusetts and prepare for the registration of its lead stem cell therapy product intended to treat fistulas in patients with Crohn’s disease.
Evotec AG has expanded its capacity to discover new drugs through the use of adult stem cells that have been reprogrammed to produce any type of cell in the human body. These induced pluripotent stem (iPS) cells can be used to model disease and identify prospective treatments.
Netherlands-based BioGeneration Ventures has secured new commitments for its third investment fund, BGV III, enabling it to expand the number of companies to which it provides seed capital. The new commitments raise the fund’s capital to €66 million.
Following an accelerated assessment, the European Medicines Agency is recommending two new combination drugs to treat infections caused by the hepatitis C virus (HCV). Both therapies are direct-acting antivirals and effective against all genotypes of the virus.
The US Food and Drug Administration has approved the first C1 esterase inhibitor for the prophylaxis of hereditary angioedema, a rare protein deficiency that can cause swelling of the limbs or airway. The product, Haegarda, was developed by CSL Behring LLC.